Lipocine Inc (LPCN)

$2.20 -0.01 (-0.45%)
Market Cap 18.22M
Revenue (ttm) 1.98M
Net Income (ttm) -9.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -486.36%
Debt to Equity Ratio 0.00
Volume 93,100
Avg Vol 473,510
Day's Range N/A - N/A
Shares Out 8.24M
Stochastic %K 21%
Beta 0.50
Analysts Hold
Price Target $6.00

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the ma...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
brunoq14
brunoq14 May. 19 at 2:31 PM
$LPCN A bit of a mindless selloff is going on. Not every stock, but quite a few.
0 · Reply
ultistock
ultistock May. 19 at 2:14 PM
$LPCN My email alerts from LPCN stopped working. Has that happened to anyone else?
1 · Reply
brunoq14
brunoq14 May. 19 at 12:29 PM
$LPCN Not only do we have 1154 data presentation on May 26, we also have a fireside chat scheduled on May 20. Check out the Lipocine website message board.
0 · Reply
TradeOrGoHome
TradeOrGoHome May. 19 at 12:09 PM
$LPCN loaded. This will see $7.
1 · Reply
DARKP00L
DARKP00L May. 19 at 12:08 PM
$LPCN 08:04 on May. 19 2026 Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26 #tradeideas
0 · Reply
amazingcrwns
amazingcrwns May. 18 at 3:15 PM
$LPCN Friendly reminder of what the data looks like when you exclude the outlier site.
2 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 13 at 6:25 PM
$LPCN Ultra-rare Stegosaurus trading pattern taking shape today. Could be Ultra-bullish if doesn't go extinct first.
1 · Reply
RunningRobert1
RunningRobert1 May. 11 at 2:48 PM
$LPCN Lipocine Inc LPCN Q1 2026 Summary 11May2026 https://youtu.be/hw_FiiFoiv4 Boring Q report, but interesting Corporate presentation, dont know if it will lead to anything but it def at least clears the way for LPCN to try another trial, paying for that trial...well we will see
1 · Reply
joe77w
joe77w May. 8 at 7:26 AM
$LPCN 3.4 USD in net equity, add pipeline, this seems way undervalued, according Just issued 10Q.
1 · Reply
amazingcrwns
amazingcrwns May. 7 at 7:47 PM
$LPCN Earnings report is out, as is the new corporate deck on the website. There is additional statistical information from the ppd trial. There is more data to support oral brex, but I'm angry about it.
2 · Reply
Latest News on LPCN
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

May 19, 2026, 8:00 AM EDT - 15 hours ago

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

May 19, 2026, 4:00 AM EDT - 19 hours ago

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

May 18, 2026, 8:00 AM EDT - 1 day ago

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

May 7, 2026, 4:05 PM EDT - 12 days ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 12 days ago

Lipocine Quarterly report: Q1 2026

Lipocine Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 12 days ago

Lipocine Earnings release: Q1 2026

Lipocine Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 12 days ago

Lipocine Slides: Corporate presentation

Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 weeks ago

Lipocine Proxy statement: Proxy filing

Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 weeks ago

Lipocine Proxy statement: Proxy filing

Lipocine price target lowered to $6 from $11 at Alliance Global

2026-04-13T18:12:07.000Z - 5 weeks ago

Lipocine price target lowered to $6 from $11 at Alliance Global

Lipocine Slides: Investor presentation

Apr 13, 2026, 7:00 AM EDT - 5 weeks ago

Lipocine Slides: Investor presentation

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr 6, 2026, 7:56 AM EDT - 6 weeks ago

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine downgraded to Neutral from Buy at H.C. Wainwright

2026-04-06T10:16:57.000Z - 6 weeks ago

Lipocine downgraded to Neutral from Buy at H.C. Wainwright

Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial

2026-04-02T12:07:46.000Z - 6 weeks ago

Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Apr 2, 2026, 8:00 AM EDT - 6 weeks ago

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 6 weeks ago

Lipocine Slides: Corporate presentation

Lipocine price target raised to $11 from $6.75 at Alliance Global

2026-03-17T16:00:59.000Z - 2 months ago

Lipocine price target raised to $11 from $6.75 at Alliance Global

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Earnings release: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Lipocine Earnings release: Q4 2025

Lipocine Annual report: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Lipocine Annual report: Q4 2025

Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

2026-02-18T13:05:35.000Z - 3 months ago

Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Feb 18, 2026, 8:00 AM EST - 3 months ago

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Lipocine Slides: Corporate presentation

Feb 18, 2026, 6:00 AM EST - 3 months ago

Lipocine Slides: Corporate presentation

Lipocine price target raised to $15 from $7 at H.C. Wainwright

2026-01-21T11:15:46.000Z - 4 months ago

Lipocine price target raised to $15 from $7 at H.C. Wainwright

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

2026-01-20T13:05:41.000Z - 4 months ago

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 20, 2026, 8:00 AM EST - 4 months ago

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

2026-01-12T13:16:24.000Z - 4 months ago

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 12, 2026, 8:00 AM EST - 4 months ago

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

2025-12-16T13:06:09.000Z - 5 months ago

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Dec 16, 2025, 8:00 AM EST - 5 months ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

2025-11-18T14:44:20.000Z - 6 months ago

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 18, 2025, 8:00 AM EST - 6 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

2025-11-13T11:20:38.000Z - 6 months ago

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

Lipocine reports Q3 EPS (59c) vs. (44c) last year

2025-11-06T13:06:28.000Z - 6 months ago

Lipocine reports Q3 EPS (59c) vs. (44c) last year

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 6 months ago

Lipocine Earnings release: Q3 2025

Lipocine Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 6 months ago

Lipocine Quarterly report: Q3 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 7 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Lipocine provides update on Phase 3 clinical trial in postpartum depression

2025-09-30T12:10:40.000Z - 8 months ago

Lipocine provides update on Phase 3 clinical trial in postpartum depression

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 30, 2025, 8:00 AM EDT - 8 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:30 PM EDT - 9 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 26, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine reports Q2 EPS (41c) vs. (57c) last year

2025-08-05T12:05:16.000Z - 10 months ago

Lipocine reports Q2 EPS (41c) vs. (57c) last year

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Lipocine Quarterly report: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Lipocine Quarterly report: Q2 2025

Lipocine Earnings release: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Lipocine Earnings release: Q2 2025

Lipocine Transcript: Status Update

Jul 9, 2025, 11:00 AM EDT - 11 months ago

Lipocine Transcript: Status Update

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

2025-06-26T12:05:39.000Z - 11 months ago

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 26, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 23, 2025, 8:00 AM EDT - 11 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Lipocine announces filing of NDA for TLANDO in Canada

2025-06-09T12:10:36.000Z - 1 year ago

Lipocine announces filing of NDA for TLANDO in Canada

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Lipocine assumed with a Buy at H.C. Wainwright

2025-05-29T14:45:19.000Z - 1 year ago

Lipocine assumed with a Buy at H.C. Wainwright

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025, 8:00 AM EDT - 1 year ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Lipocine Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

May 21, 2025, 4:00 PM EDT - 1 year ago

Lipocine Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Lipocine Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Earnings release: Q1 2025

Lipocine Quarterly report: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Quarterly report: Q1 2025

Lipocine announces license and supply agreement with Ache

2025-05-06T12:17:57.000Z - 1 year ago

Lipocine announces license and supply agreement with Ache

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Lipocine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing

Lipocine Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing

Lipocine initiates Phase 3 trial for LPCN 1154

2025-03-26T12:06:51.000Z - 1 year ago

Lipocine initiates Phase 3 trial for LPCN 1154

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine price target lowered to $6.75 from $10 at Alliance Global Partners

2025-03-19T11:05:23.000Z - 1 year ago

Lipocine price target lowered to $6.75 from $10 at Alliance Global Partners

Lipocine Earnings release: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Earnings release: Q4 2024

Lipocine Annual report: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Annual report: Q4 2024

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces FDA Labeling Changes for Testosterone Products

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Press release: Corporate Presentation

Dec 12, 2024, 7:00 PM EST - 1 year ago

Lipocine Press release: Corporate Presentation

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Quarterly report: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Quarterly report: Q3 2024

Lipocine Earnings release: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Earnings release: Q3 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Transcript: Status Update

Oct 15, 2024, 6:00 PM EDT - 1 year ago

Lipocine Transcript: Status Update

Lipocine Slides: Status Update

Oct 15, 2024, 6:00 PM EDT - 1 year ago

Lipocine Slides: Status Update

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Lipocine Quarterly report: Q2 2024

Lipocine Earnings release: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Lipocine Earnings release: Q2 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Lipocine Proxy statement: Proxy Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Quarterly report: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Quarterly report: Q1 2024

Lipocine Earnings release: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Earnings release: Q1 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

May 1, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Registration statement: Registration Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Registration statement: Registration Filing

Lipocine Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Transcript: Study Result

Apr 10, 2024, 6:00 PM EDT - 2 years ago

Lipocine Transcript: Study Result

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Lipocine Annual report: Q4 2023

Mar 6, 2024, 6:00 PM EST - 2 years ago

Lipocine Annual report: Q4 2023

Lipocine Earnings release: Q4 2023

Mar 6, 2024, 6:00 PM EST - 2 years ago

Lipocine Earnings release: Q4 2023

Lipocine to Present at 36th Annual Roth Conference

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference

brunoq14
brunoq14 May. 19 at 2:31 PM
$LPCN A bit of a mindless selloff is going on. Not every stock, but quite a few.
0 · Reply
ultistock
ultistock May. 19 at 2:14 PM
$LPCN My email alerts from LPCN stopped working. Has that happened to anyone else?
1 · Reply
brunoq14
brunoq14 May. 19 at 12:29 PM
$LPCN Not only do we have 1154 data presentation on May 26, we also have a fireside chat scheduled on May 20. Check out the Lipocine website message board.
0 · Reply
TradeOrGoHome
TradeOrGoHome May. 19 at 12:09 PM
$LPCN loaded. This will see $7.
1 · Reply
DARKP00L
DARKP00L May. 19 at 12:08 PM
$LPCN 08:04 on May. 19 2026 Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26 #tradeideas
0 · Reply
amazingcrwns
amazingcrwns May. 18 at 3:15 PM
$LPCN Friendly reminder of what the data looks like when you exclude the outlier site.
2 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 13 at 6:25 PM
$LPCN Ultra-rare Stegosaurus trading pattern taking shape today. Could be Ultra-bullish if doesn't go extinct first.
1 · Reply
RunningRobert1
RunningRobert1 May. 11 at 2:48 PM
$LPCN Lipocine Inc LPCN Q1 2026 Summary 11May2026 https://youtu.be/hw_FiiFoiv4 Boring Q report, but interesting Corporate presentation, dont know if it will lead to anything but it def at least clears the way for LPCN to try another trial, paying for that trial...well we will see
1 · Reply
joe77w
joe77w May. 8 at 7:26 AM
$LPCN 3.4 USD in net equity, add pipeline, this seems way undervalued, according Just issued 10Q.
1 · Reply
amazingcrwns
amazingcrwns May. 7 at 7:47 PM
$LPCN Earnings report is out, as is the new corporate deck on the website. There is additional statistical information from the ppd trial. There is more data to support oral brex, but I'm angry about it.
2 · Reply
DivvyDoo
DivvyDoo May. 6 at 4:14 PM
$LPCN interesting that SPTX is actually 53M shares OS close to 850M MC. Management team ex -Karuna. Glyph vs Lipral.
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 6 at 3:16 PM
$LPCN There's gold in them hills.
0 · Reply
BillionerOfKing
BillionerOfKing May. 4 at 9:32 AM
$LPCN Current Stock Price: $2.35
2 · Reply
DivvyDoo
DivvyDoo May. 2 at 2:50 PM
$LPCN Seaport IPO - valued around 280M - https://seaporttx.com/our-pipeline/
0 · Reply
steven1x
steven1x Apr. 30 at 7:54 PM
$LPCN https://g.co/gemini/share/8ef478f5edba
1 · Reply
BaneMan666
BaneMan666 Apr. 24 at 9:55 PM
$LPCN Lipocine’s FAST ACTING SAFE oral drug for the most severe psychiatric disorder patients is best option! The FDA announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. It's a significant step toward supporting psychedelic-based medicines for conditions such as treatment-resistant depression, PTSD and other substance use disorders, the agency said. The FDA also said allowing these studies to proceed does not mean the drugs are approved or proven safe and effective and that data must be closely monitored.
1 · Reply
amazingcrwns
amazingcrwns Apr. 24 at 1:15 PM
$LPCN Not much happening here for the next several weeks. I'm looking forward to the earnings report for the latest financials after ATM usage and maybe some indication of what their plans are, and then maybe a new slide deck before the annual meeting on June 3rd. I believe its still several weeks before they'll complete their full analysis of the data and submit it to the FDA. Its probably a similar timeline for them to get a response to the FastTrack and BTD applications. Then another few months for the FDA to review the complete dataset and give a response. Probably going to be a quiet summer, hopefully we get canadian approval for Tlando at some point and maybe they'll sign a new regional supplier deal or something.
1 · Reply
bg4
bg4 Apr. 22 at 6:35 PM
$LPCN Dr. R. Dana Ono's background strongly suggests that he is a specialist in preparing companies for sale or strategically repositioning them.
4 · Reply
frontiere
frontiere Apr. 22 at 2:16 PM
$NEUP Neuphoria ex $BNOX Bionomics — Long — anyone here picked up on CEO Spyros resigning from his $LPCN Lipocine Chairmanship with a disagreement? Breadcrumbs, but I see it as a small good sign — I was a bit wary of how actively he is involved in NEUP right now. Also LPCN is an interesting cigar butt long if goes <$2.00 again ;)
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 8:30 PM
$LPCN Lipocine Appoints R. Dana Ono As Chairman Of The Board On April 20, 2026
2 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 2:36 PM
$LPCN Bullish MACD crossover on daily. Mega gap over 2.63 NOTE: Insiders purchased recently a ton of shares $434,600 in total value
1 · Reply